| Identification | Back Directory | [Name]
L-Threoninamide, N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-α-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-, cyclic (2→12)-disulfide | [CAS]
934461-40-2 | [Synonyms]
POT-4
(Trp(me)4)-ac-compstatin
L-Threoninamide, N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-α-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-, cyclic (2→12)-disulfide | [Molecular Formula]
C72H102N22O18S2 | [MOL File]
934461-40-2.mol | [Molecular Weight]
1627.86 |
| Hazard Information | Back Directory | [Uses]
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research[1][2] | [storage]
Store at -20°C | [References]
[1] S. Kaushal, et al. Complement C3 inhibitor POT-4: Clinical Safety of Intravitreal Administration. ARVO Annual Meeting Abstract, 2009 Apr.
[2] Robyn Troutbeck, et al. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clin Exp Ophthalmol. Jan-Feb 2012;40(1):18-26. DOI:10.1111/j.1442-9071.2011.02581.x |
|
|